Lee’s Pharmaceutical Holdings Limited (HK:0950) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lee’s Pharmaceutical Holdings Limited has announced that China’s National Medical Products Administration has accepted their IND application for Recombinant Anfibatide Injection, marking a significant step towards clinical trials for this novel anti-thrombosis drug. The injection, developed by Lee’s Pharm’s subsidiary, Zhaoke Pharmaceutical, demonstrates potential in preventing thrombotic conditions like myocardial infarction. This development underscores Lee’s Pharm’s commitment to innovation in biopharmaceuticals, with a focus on cardiovascular and rare disease therapeutics.
For further insights into HK:0950 stock, check out TipRanks’ Stock Analysis page.